drugset / Trial / NCT06722430

A Study to Assess Change in How Oral Icalcaprant With Itraconazole Moves Through the Body in Healthy Adult Participants

NCT06722430

Phase 1 Completed 12 enrolled AbbVie
NaSingle-groupOpen-labelBasic science

Summary

This study is to assess the change of itraconazole, a strong CYP3A inhibitor, on the pharmacokinetics, safety, and tolerability of a single dose of icalcaprant in healthy participants.

Timeline

Start
2024-11-13
Primary completion
2025-01-13
Completion
2025-01-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Icalcaprant Small molecule Oral
Background Itraconazole Small molecule Oral

Indications

No indication recorded.